Skeletal muscle strength and endurance in recipients of lung transplants.
Lung transplantation is a highly beneficial treatment resulting in improved survival rates and quality of life in people with end-stage, chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD), cystic fibrosis, and restrictive lung diseases. (1) Although pulmonary function improves following lung transplantation, recipients of lung transplants still experience limited exercise capacity (40% to 60% of predicted) even up to 1 year following the transplant. (2,3) Exercise limitation has been attributed to factors related to oxygen delivery and utilization by skeletal muscle (4,5) and changes in the metabolic properties of skeletal muscle in lung transplant recipients. (5,6) Reinsma et al (7) examined factors limiting exercise capacity in people with varying pretransplant diagnoses, both before and 1 year following transplant and suggested that peripheral muscle dysfunction was the major contributor to limited exercise capacity post-transplant. Skeletal muscle abnormalities in transplant recipients have been attributed to a prolonged period of bedrest and low activity levels pre--and post-transplant and the use of immunosuppressant medications such as calcineurin inhibitors and corticosteroids. (1,7)
Skeletal muscle abnormalities beyond the metabolic characteristics of muscle have not been studied extensively in recipients of lung transplants. Muscle mass, strength, and endurance are important characteristics of skeletal muscle that may also be affected by inactivity and the secondary effects of medications. Furthermore, the pretransplant condition (ie, COPD) is associated with reduced muscle mass (8) and muscle fiber atrophy, (9) muscle weakness, (10) and reduced muscle endurance (11) compared to healthy people of the same age. Following lung transplantation, these characteristics of skeletal muscle may be further impaired.
The majority of studies examining exercise capacity and/or skeletal muscle characteristics in people with lung transplant either do not include a control group (12,13) or compare them to a healthy control group. (4-6,14,15) However, to determine whether the changes observed in skeletal muscle are due to the pretransplant condition or to factors related to post-transplant care, comparisons need to be made to people who have a chronic respiratory condition. Since COPD is known to be associated with skeletal muscle abnormalities and is also a major indication for lung transplantation, (16) it provides an excellent model for comparison to determine whether skeletal muscle changes observed following lung transplant are merely a reflection of the pretransplant condition or whether they are worsened post-transplant.
The purpose of this paper was to compare the muscle volume, intramuscular fat infiltration, and strength of individual muscle groups of the thigh, and muscle endurance of the quadriceps in people with COPD and restrictive lung disease who were recipients of lung transplants (lung transplant group) to those who had not undergone lung transplant (COPD group). We hypothesized that lung transplant recipients would have greater impairments in skeletal muscle (ie, lower muscle volume, strength, and endurance) than the COPD group.
Recipients of single lung transplant were recruited from the Solid Organ Transplant Clinic over a 1 year period (2003-2004). Single lung transplant is the preferred procedure in people with COPD or pulmonary fibrosis at our center. Letters were sent to potential participants and 10 lung transplant recipients volunteered to participate in this study, of which 6 met the inclusion criteria (see Table 1). People with COPD were recruited from patient lists at the respiratory clinic and pulmonary function labs. Specific inclusion criteria are provided in Table 1. People with COPD were matched to the recipients of lung transplant based on sex, age ([+ or -] 4 years), and BMI ([+ or -] 2.0 kg/[m.sup.2]). Subjects with COPD had a stable condition and none were awaiting lung transplant.
The study was approved by the local University Clinical Research Ethics Board and all subjects provided written, informed consent. Each participant completed the Physical Activity Scale for the Elderly (PASE). (17) The PASE is a 12-item, self-administered questionnaire that asks about household, leisure time, and work-related physical activity over the past 7-day period. Height and weight were measured with shoes off and light clothing.
Lung Function and Exercise Testing
Participants underwent spirometry according to American Thoracic Society standards (18) to measure forced expiratory volume in one second ([FEV.sub.1]) and forced vital capacity (FVC). Values were expressed as percent of predicted. (19) For lung transplant recipients, bronchiolitis obliterans syndrome (BOS) stage was calculated by comparing the average of 2 measurements of [FEV.sub.1] made at least 3 weeks apart to the subject's previously established baseline [FEV.sub.1]. (20) Any decline in [FEV.sub.1] was staged according to published guidelines. (20)
An incremental exercise test was conducted on an electrically-braked cycle ergometer. Workload was increased by 10 Watts per minute until symptom-limited maximum was achieved. Participants were connected to a metabolic cart (VMax 229, Sensormedics, Yorba Linda, Calif) which consisted of a pneumotachograph, [O.sub.2] and C[O.sub.2] analysers, and a mixing chamber. Breath-by-breath analysis was used to obtain minute ventilation ([V.sub.E]), oxygen uptake (V[O.sub.2]), and carbon dioxide production (VC[O.sub.2]). Heart rate was monitored using 12-lead ECG (Quinton Eclipse Premier, Bothell, Wash) and oxygen saturation (% Sp[O.sub.2]) was monitored using a finger pulse oximeter (SiMed S103, Miami, Fla). Blood pressure was measured manually at rest and one minute intervals throughout the test. Participants were asked to rate shortness of breath and leg fatigue separately throughout the test using the Rating of Perceived Exertion (RPE) category-ratio scale. (21) Peak V[O.sub.2] and workrate were expressed as a percent of predicted. (22)
An MRI was used to estimate quadriceps, hamstrings, and adductor muscle volume as previously described. (23) Briefly, a 1.5 Tesla MRI scanner (1.5T Echospeed Scanner, General Electric, Milwaukee, Wis) was used to acquire 5-mm axial contiguous slices from the femoral-tibial joint line to the anterior superior iliac spine on both thighs. Images were T1-weighted (TE = 8 ms; TR = 650 ms) with a 40[cm.sup.2] field of view and a 512 x 224 pixel matrix (in-plane spatial resolution = 0.78 x 1.78 mm).
NIH Image, version 1.3.1 (http://rsb.info.nih.gov/ij/ Java1.3.1._03) was used to manually outline the quadriceps [rectus femoris (RF), the vasti (vastus lateralis, vastus intermedius, and vastus medialis)], hamstrings (semitendinosis, semimembranosis, biceps femoris long head and short head) and the adductors (adductors longus, brevis, and magnus). Muscles were outlined on 17 slices, with a gap of 2.0 to 2.5 cm between measured slices. The first slice was chosen at the origin of the RF muscle (approximately 2 cm below the anterior inferior iliac spine) and the last slice was at the superior aspect of the patella. The distance between the first and last slices was divided equally into 16 slices. The total volume of the muscle was calculated by summing the product of measured muscle cross-sectional areas by the slice thickness of all 17 sections, and the volume of the gaps between slices was estimated using the truncated cone formula as previously described. (24) Individual muscles are shown in Figure 1A and Figure 1B.
Intramuscular fat infiltration
To determine the degree of intramuscular fat infiltration, the RF, vasti, semitendinosis, and biceps femoris (long head) were outlined on the mid-thigh slice and NIH Image was used to generate a frequency distribution of signal intensity for each muscle (Figure 1C). The interquartile range (IQR), ie, the number of pixels in the 25th to 75th percentile of signal intensity, was calculated for each distribution and a greater IQR was indicative more fat infiltration. (25) Secondly, a coefficient of skewness was calculated to describe the asymmetry of the frequency distribution. A normal distribution is symmetric, and has a skewness value of zero whereas a distribution with a significant positive skewness has a long right tail indicative of pixels with higher signal intensity, ie, greater fat. (25)
Peak torque of the knee extensors (KEs) and flexors (KFs)
Concentric and eccentric torque of the KEs and KFs were performed on the KinCom dynamometer (version 5.30, Chattanooga Group Inc, Hixson, Tenn) which is a valid and reliable instrument for measuring torque. (26,27) Each participant was seated on the dynamometer with straps placed across the hips and shoulders, and the knee joint carefully aligned with the axis of rotation of the dynamometer. The shin pad was placed at 75% of the distance from the head of the fibula to the distal edge of the lateral malleolus. Each participant performed 5 submaximal warm-up contractions followed by 3 to 4 maximal voluntary concentric and eccentric contractions at 30[degrees]/s through a range of motion from 100[degrees] of flexion to full available extension. Peak torques of the KEs and KFs were normalized to muscle volume of the quadriceps and hamstrings, respectively and expressed in Nm/[cm.sup.3].
Each participant performed a KE muscle endurance task consisting of an isometric contraction held at 80% of their maximal voluntary isometric contraction (MVIC) on the KinCom dynamometer. The knee joint was placed at 90[degrees] of flexion for testing. The MVIC was determined from 3 MVICs of the KEs with a 1 minute break given between trials. The participant was instructed to "push as hard as possible" over a 5-second period. The highest value was used to calculate the target torque for the endurance task (80% MVIC).
Following a 5-minute rest the endurance task was performed. During the endurance task the subject was asked to maintain their target torque for as long as possible. Visual feedback of the target and produced torque was provided and verbal encouragement was given by the tester to maintain the force at the target level until the target torque could no longer be met despite verbal cueing. The time to task failure was defined as the point where the produced torque dropped 20% from the target level and was calculated from the software program. The participant was asked to rate their leg fatigue at the end of the contraction using the RPE scale.
Descriptive statistics (mean and standard deviation) were used to describe subject characteristics, muscle volume, torque, and endurance time. The mean difference and 95% confidence interval (95% CI) for the difference between the groups was calculated from one-way ANOVA, and the level of significance was set at [alpha]= 0.05. The 95% CI is helpful in determining whether a clinical meaningful difference exists, especially when comparing small samples of subjects. Post-hoc power analysis was completed using statistical software package, G-Power (version 3). (28) Effect size was calculated as the difference between the group means divided by the average of the standard deviations observed from each group for the measure of interest [(mean1 - mean2)/SD].
Recipients of lung transplant and people with COPD were closely matched for sex, age, height, weight, and BMI (Table 2). As shown in Table 3, all recipients of lung transplant were receiving a regimen of immunosuppressant medications consisting of a calcineurin inhibitor (cyclosporine or tacrolimus), a purine synthesis inhibitor (azathioprine or mycophenalate mofetil), and a corticosteroid (ie, prednisone). Recipients of lung transplant were not showing significant chronic allograft dysfunction (BOS scores 0-1).
Recipients of lung transplant all received single lung transplants and their lung function was lower than predicted values ([FEV.sub.1] = 63% [+ or -] 9% of predicted and FVC = 68 [+ or -] 10% of predicted), however, were higher than in people with COPD (p < 0.01) (see Table 2). Peak V[O.sub.2] was limited in both groups compared to predicted values: 59% and 53% of predicted in transplant recipients and people with COPD, respectively. All subjects reported leg fatigue to be greater than shortness of breath at the end of exercise using the RPE scale.
[FIGURE 1 OMITTED]
Each subject's quadriceps, hamstrings, and adductor muscle volumes are shown Figure 2. Muscle volume tended to be lower in the transplant recipients compared to people with COPD by 6.5% for the quadriceps (mean difference = -83.6, 95% CI = -594.2 to 426.6 [cm.sup.3]), 2.3% for the hamstrings (mean difference = -11.6, 95% CI = -189.6 to 166.3 [cm.sup.3]), and 13.8% for the adductors (mean difference = -87.9, 95% CI = -375.2 to 199.4 [cm.sup.3]); however, no significant difference was observed between groups (p = 0.71 to 0.98).
Intramuscular fat infiltration
Interquartile range and coefficients of skewness were used to quantify the degree of intramuscular fat infiltration in individual muscles on the thigh (Table 4). Lung transplant recipients and people with COPD showed the presence of intramuscular fat, as shown by coefficients of skewness greater than one; however there was no significant difference observed between the groups (p = 0.14 to 0.99).
Absolute and Normalized Torque of KEs and KFs
Knee extensors and knee flexors absolute torques are shown in Figure 3. The largest mean difference between groups was seen for the KE eccentric torque (15 Nm, 95% CI = -56 to 26 Nm), however other mean differences were small, ranging from no difference (ie, 0) to 6 Nm. The KE and KF torques were then normalized for quadriceps and hamstrings muscle volumes, respectively, to account for differences in muscle volume between subjects (Figure 4). Mean differences between groups for normalized torque were small, ranging from 0.0003 to 0.008.
Quadriceps muscle endurance
Endurance times for individual recipients of lung transplant and people with COPD are shown in Figure 5. Although initial isometric torque was similar between groups (75 [+ or -] 27 N/m in transplant compared to 71 [+ or -] 18 N/m in COPD), mean isometric endurance time had a tendency to be lower in transplant recipients compared to COPD (mean difference of -13 seconds, 95% CI= -29 to 2, p=0.08). Rating of perceived exertion for leg fatigue at the end of the endurance task was also similar between groups (6 [+ or -] 1 and 7 [+ or -] 1 in transplant and COPD, respectively).
[FIGURE 2 OMITTED]
The main findings of this study demonstrate that recipients of lung transplant have similar muscle volumes of the thigh, a similar degree of intramuscular fat infiltration, and similar strength of the KEs and KFs compared to people with pre-existing chronic respiratory disease, mainly COPD. However, isometric endurance of the quadriceps muscle tended to be lower in recipients of lung transplant compared to people with COPD. Our study is unique since it compared a group of people with lung transplant to people with COPD who were matched for sex, age, and BMI. This allowed us to draw comparisons between pre-existing muscle dysfunction associated with COPD to that which occurs following lung transplant. Our findings indicate that muscle mass, composition, and strength are likely affected to a similar degree in recipients of lung transplant as compared to people with COPD, whereas muscle endurance may show a tendency to be lower in transplant recipients.
This study is the first to quantify muscle volume of 3 muscle groups of the thigh in people with lung transplants using specific measurements from MRI. We found that volumes of the quadriceps, hamstrings, and adductors in people with lung transplants were similar to those seen in the COPD group, although there was a tendency for the transplant group to have a lower mean volume than people with COPD. A post-hoc power analysis indicated that a sample of at least 50 subjects per group would be required to determine whether recipients of lung transplant actually show a lower muscle volume than people with COPD. A previous study showed that quadriceps cross-sectional area was 31% lower in recipients of lung transplants who had cystic fibrosis compared to age-matched controls (15) whereas patients with COPD have been reported to have a mid-thigh cross-sectional area which is 24% of controls. (8)
People with lung transplant also showed a similar degree of intramuscular fat infiltration compared to people with COPD. We have previously showed that people with COPD have higher fat infiltration in their thigh muscles compared to age, sex, and BMI-matched controls. (25) The presence of fat infiltration in recipients of lung transplant may be associated with muscle atrophy as has been reported in older individuals or as a result of steroid-induced muscle myopathy. (29) Fat infiltration may contribute to poor muscle function (ie, strength) (30) and also to metabolic complications. (31)
Although pulmonary function is improved following single lung transplantation, factors that affect muscle mass and muscle quality in people with chronic lung disease, pretransplant, such as inactivity, corticosteroid medications, nutritional factors, oxidative stress, and systemic inflammation (32) are likely to play a persistent role in muscle atrophy following transplant. Rehabilitative strategies that are used in people with COPD to improve muscle mass and strength such as resistance training (33) as well as nutritional (34) and hormonal supplementation, (35) may also be beneficial in the rehabilitation of people with lung transplant and require further investigation in this population.
Peripheral muscle force has been reported to be lower in recipients of lung transplant compared to a matched control group (14) and also compared to predicted values. (7,13) Furthermore, Reinsma et al (7) showed that one year following lung transplantation, isometric quadriceps muscle force still only reached 67 [+ or -] 19% of predicted, compared to 62 [+ or -] 19% in the same subjects prior to transplant. Similarly, we found that compared to people with COPD, people with lung transplant had similar concentric and eccentric torque of the KEs and KFs. As there were differences between individuals in muscle volume, we also normalized torque of the KEs and KFs to muscle volume of the quadriceps and hamstrings and found that normalized torque was also similar between groups. Since muscle mass is a major contributor to muscle strength, (8) muscle atrophy likely plays an important role in the loss of muscle strength in transplant recipients and needs to be addressed through rehabilitation.
[FIGURE 3 OMITTED]
[FIGURE 4 OMITTED]
Quadriceps endurance time tended to be shorter in recipients of lung transplant compared to people with COPD. The observed effect size for this difference was 1.62 and to obtain a significant difference between groups, a sample of at least 9 subjects per group would have been needed. As the quadriceps endurance task depended primarily on anaerobic metabolism since it was a high intensity, isometric contraction (80% of MVIC), (36) our findings likely reflect impairments in anaerobic metabolism, which is consistent with previous studies. For instance, Evans et al (4) showed that recipients of lung transplant had a lower resting pH of the quadriceps muscles and an earlier drop in pH during bilateral knee extension exercise to exhaustion. This suggests that there is an earlier onset of glycolytic metabolism in people with lung transplant with exercise that can limit endurance. Impairments in the metabolic properties of skeletal muscle of recipients of lung transplant may be due to the secondary effects of immunosuppressant medications that affect calcium handling. Calcium uptake and release by the sarcoplasmic reticulum and potassium homeostasis across the sarcolemma are important aspects of skeletal muscle contractility and are linked to muscle fatigue in humans. (37) Abnormalities in skeletal muscle calcium and potassium regulation have been observed in lung transplant recipients and may result in impairments in excitation-contraction coupling and contribute to the early onset of muscle fatigue. (37)
Our study reports preliminary findings in a small sample of people following lung transplant, compared to people with chronic lung diseases, mainly COPD. Although our study lacked adequate power to determine statistical significance, this comparison provides insight as to whether skeletal muscle dysfunction following lung transplant is merely a reflection of abnormalities observed in people with chronic lung disease or whether changes in skeletal muscle persist or are accentuated following lung transplant. Furthermore, this study included subjects with a large range of time since transplant (14 to 84 months), which likely introduced an additional source of variance to the data. To address these issues further, a larger, longitudinal study design, which follows people with chronic lung diseases both before and after transplant over a long term, needs to be conducted.
We also included 1 subject who had a pretransplant diagnosis of sarcoidosis, however, this likely did not affect our results, since skeletal muscle changes have been shown to be similar to people with COPD (38) and this subject was also of a similar age to the other subjects in the COPD group.
Recipients of lung transplants show similar changes in muscle mass, intramuscular fat infiltration, and muscle strength as people with chronic lung disease. Muscle endurance, however, may show a tendency to be affected to a greater degree in recipients of lung transplants. This may be result of factors which are present post-transplant, such as the secondary effects of immunosuppressant medications on skeletal muscle. Similar rehabilitative strategies used to improve muscle mass and strength in people with COPD, such as resistance exercise training, may also be applicable to lung transplant recipients.
The authors would like to acknowledge funding for this study from the Canadian Institutes of Health Research (CIHR) and British Columbia Medical Services Foundation. The authors would also like to thank the Solid Organ Transplant Clinic at Vancouver General Hospital, the Pulmonary Function Lab at Vancouver General Hospital and the GF Strong Rehabilitation Research Lab for assistance with subject testing.
(1.) Studer SM, Levy RD, McNeil K, Orens JB. Lung transplant outcomes: a review of survival, graft function, physiology, health-related quality of life and cost-effectiveness. Eur Respir J. 2004;24:674-685.
(2.) Miyoshi S, Trulock EP, Schaefers HJ, Hsieh CM, Patterson GA, Cooper JD. Cardiopulmonary exercise testing after single and double lung transplantation. Chest. 1990;97:1130-1136.
(3.) Williams TJ, Patterson GA, McClean PA, Zamel N, Maurer JR. Maximal exercise testing in single and double lung transplant recipients. Am Rev Respir Dis. 1992;145:101-105.
(4.) Evans AB, Al-Himyary AJ, Hrovat MI, et al. Abnormal skeletal muscle oxidative capacity after lung transplantation by 31P-MRS. Am J Respir Crit Care Med. 1997;155:615-621.
(5.) Tirdel GB, Girgis R, Fishman RS, Theodore J. Metabolic myopathy as a cause of the exercise limitation in lung transplant recipients. J Heart Lung Transplant. 1998;17:1231-1237.
(6.) Wang XN, Williams TJ, McKenna MJ, et al. Skeletal muscle oxidative capacity, fiber type, and metabolites after lung transplantation. Am J Respir Crit Care Med. 1999;160:57-63.
(7.) Reinsma GD, ten Hacken NH, Grevink RG, van der Bij W, Koeter GH, van Weert E. Limiting factors of exercise performance 1 year after lung transplantation. J Heart Lung Transplant. 2006;25:1310-1316.
(8.) Bernard S, LeBlanc P, Whittom F, et al. Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;158:629-634.
(9.) Whittom F, Jobin J, Simard PM, et al. Histochemical and morphological characteristics of the vastus lateralis muscle in patients with chronic obstructive pulmonary disease. Med Sci Sports Exerc. 1998;30:14671474.
(10.) Gosselink R, Troosters T, Decramer M. Distribution of muscle weakness in patients with stable chronic obstructive pulmonary disease. J Cardiopulm Rehabil. 2000;20:353-360.
(11.) Allaire J, Maltais F, Doyon JF, et al. Peripheral muscle endurance and the oxidative profile of the quadriceps in patients with COPD. Thorax. 2004;59:673-678.
(12.) Lands LC, Smountas AA, Mesiano G, et al. Maximal exercise capacity and peripheral skeletal muscle function following lung transplantation. J Heart Lung Transplant. 1999;18:113-120.
(13.) Van Der Woude BT, Kropmans TJ, Douma KW, et al. Peripheral muscle force and exercise capacity in lung transplant candidates. Int J Rehabil Res. 2002;25:351355.
(14.) Pantoja JG, Andrade FH, Stoki DS, Frost AE, Eschenbacher WL, Reid MB. Respiratory and limb muscle function in lung allograft recipients. Am J Respir Crit Care Med. 1999;160:1205-1211.
(15.) Pinet C, Scillia P, Cassart M, et al. Preferential reduction of quadriceps over respiratory muscle strength and bulk after lung transplantation for cystic fibrosis. Thorax. 2004;59:783-789.
(16.) Meyers BF, Patterson GA. Chronic obstructive pulmonary disease. 10: Bullectomy, lung volume reduction surgery, and transplantation for patients with chronic obstructive pulmonary disease. Thorax. 2003;58:634-638.
(17.) Washburn RA, Smith KW, Jette AM, Janney CA. The physical activity scale for the elderly (PASE): development and evaluation. J Clin Epidemiol. 1993;46:153-162.
(18.) American Thoracic Society/European Respiratory Society. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. A statement of the American Thoracic Society and European Respiratory Society. Am J Respir Crit Care Med. 1999;159:S1-40.
(19.) Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis. 1981;123:659-664.
(20.) Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant. 2002;21:297-310.
(21.) Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982;14:377-381.
(22.) Jones NL, Makrides L, Hitchcock C, Chypchar T, McCartney N. Normal standards for an incremental progressive cycle ergometer test. Am Rev Respir Dis. 1985;131:700-708.
(23.) Mathur S, MacIntyre DL, Forster BB, Reid WD. Influence of exercise-induced injury on knee extension torque in the presence of longstanding quadriceps atrophy: A case report. Physiother Can. 2005;57:305-313.
(24.) Tracy BL, Ivey FM, Jeffrey Metter E, Fleg JL, Siegel EL, Hurley BF. A more efficient magnetic resonance imaging-based strategy for measuring quadriceps muscle volume. Med Sci Sports Exerc. 2003;35:425-433.
(25.) Mathur S, MacIntyre DL, Forster BB, Road JD, Levy RD, Reid WD. Preservation of eccentric torque of the knee extensors and flexors in patients with COPD. J Cardiopulm Rehabil Prev. 2007;27:411-416.
(26.) Farrell M, Richards JG. Analysis of the reliability and validity of the kinetic communicator exercise device. Med Sci Sports Exerc. 1986;18:44-49.
(27.) Mayhew TP, Rothstein JM, Finucane SD, Lamb RL. Performance characteristics of the Kin-Com dynamometer. Phys Ther. 1994;74:1047-1054.
(28.) Faul F, Erdfelder E, Lang A, Buchner A. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39:175-191.
(29.) Decramer M, de Bock V, Dom R. Functional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996;153:1958-1964.
(30.) Visser M, Kritchevsky SB, Goodpaster BH, et al. Leg muscle mass and composition in relation to lower extremity performance in men and women aged 70 to 79: the health, aging and body composition study. J Am Geriatr Soc. 2002;50:897-904.
(31.) Goodpaster BH, Thaete FL, Simoneau JA, Kelley DE. Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes. 1997;46:1579-1585.
(32.) Casaburi R. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. Med Sci Sports Exerc. 2001;33:S662-670.
(33.) BernardS, Whittom F, Leblanc P, et al. Aerobic and strength training in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;159:896-901.
(34.) Steiner MC, Barton RL, Singh SJ, Morgan MD. Nutritional enhancement of exercise performance in chronic obstructive pulmonary disease: a randomised controlled trial. Thorax. 2003;58:745-751.
(35.) Casaburi R, Bhasin S, Cosentino L, et al. Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;170:870-878.
(36.) Sjogaard G, Savard G, Juel C. Muscle blood flow during isometric activity and its relation to muscle fatigue. Eur J Appl Physiol Occup Physiol. 1988;57:327-335.
(37.) McKenna MJ, Fraser SF, Li JL, et al. Impaired muscle [Ca.sup.2+] and [K.sup.+] regulation contribute to poor exercise performance post-lung transplantation. J Appl Physiol. 2003;95:1606-1616.
(38.) Spruit MA, Thomeer MJ, Gosselink R, et al. Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status. Thorax. 2005;60:32-38.
Sunita Mathur, PT, PhD;  Robert D. Levy, MD, FRCPC;  W. Darlene Reid, PT, PhD 
 School of Human Kinetics, University of British Columbia, Vancouver, BC
 British Columbia Transplant Society, Vancouver, BC
 Division of Physical Therapy, University of British Columbia, Vancouver, BC
Address correspondence to:
Sunita Mathur, Muscle Biophysics Lab
Vancouver Coastal Health Research Institute, Research
Pavilion, Room 500, 828 W 10th Ave, Vancouver
BC V5Z 1L8 CANADA
Table l. Specific Inclusion Criteria for Transplant Recipients and People with COPD General Criteria No lower extremity musculoskeletal limitations that affect exercise (eg, knee or hip joint pain, arthritis or surgery) No history of neurological conditions (e.g. stroke, Parkinson's), cardiovascular disease (eg, myocardial infarction) or metabolic disease (e.g. diabetes) Not involved in a structured exercise program Transplant > 6 months post-transplant recipients Stable on immunosuppressant medications for > 90 days No use of supplemental oxygen No recent illness or hospitalization (within last 3 months) No smoking post-transplant COPD No smoking in past 1 year No use of supplemental oxygen at rest or during exercise No oral corticosteroid use in past 12 months No recent illness or hospitalization (within last 3 months) Table 2. Sample Characteristics Transplant COPD Sex 4M: 2 F 4M: 2 F Age (years) 62.8 [+ or -] 5.1 66.8 [+ or -] 4.4 Height (m) 1.71 [+ or -] 0.08 1.66 [+ or -] 0.12 Weight (kg) 68.4 [+ or -] 18.0 73.2 [+ or -] 12.4 BMI (kg/m2) 23.4 [+ or -] 5.6 26.6 [+ or -] 3.5 PASE 106 [+ or -] 39 58 [+ or -] 20 [FEV.sub.1] (L) 1.93 t 0.31 * 1.14 [+ or -] 0.20 (% predicted) (63 [+ or -] 9%) (42 [+ or -] 13%) FVC (L) 2.70 [+ or -] 0.41 2.48 [+ or -] 0.48 (% predicted) (68 [+ or -] 10%) (68 [+ or -] 6%) [FEV.sub.1]/FVC 72 [+ or -] 7%* 47 [+ or -] 12% Peak work rate (W) 80 [+ or -] 20 70 [+ or -] 20 V[O.sub.2] (ml/kg/min) 15.0 [+ or -] 3.1 12.1 [+ or -] 2.6 (% predicted) (59 [+ or -] 12%) (53 [+ or -] 5%) [V.sub.E]/MVV (%) 78 [+ or -] 4% 73 [+ or -] 4% Heart rate max (bpm) 129 [+ or -] 17 147 [+ or -] 20 (% of age-predicted) (82 [+ or -] 8%) (96 [+ or -] 10%) Sp[O.sub.2] end exercise (%) 98 [+ or -] 1 97 [+ or -] 2 RPE (dyspnea) 6 [+ or -] 2 5 [+ or -] 2 RPE (leg fatigue) 9 [+ or -] 1 6 [+ or -] 2 * p < 0.01 Abbreviations: BMI = body mass index, [FEV.sub.1] = forced expiratory volume in one second, FVC = forced vital capacity, MVV = maximal voluntary ventilation, PASE = Physical Activity Scale for the Elderly, RPE = rating of perceived exertion, Sp[O.sub.]2 = saturation of oxygen, [V.sub.E] = minute ventilation, V[O.sub.2] = oxygen consumption, W = watts Table 3. Specific Characteristics of Lung Transplant Recipients Pre-Tx Time since BOS * Medications diagnosis transplant Stage (months) 1 sarcoidosis 14 0 CSA, MMF, Pred (20mg) ** 2 COPD 19 0 CSA, MMF, Pred (20mg) 3 COPD 45 0 Tacro, AZA, Pred (15mg) 4 COPD 28 1 Tacro, AZA, Pred (20mg) 5 COPD 84 1 Tacro, MMF, Pred (10mg) 6 COPD 44 0 CSA, MMF, Pred (15 mg) Abbreviations: Tacro = Tacrolimus, MMF = mycophenolate, Pred = Prednisone, CSA = Cyclosporine, AZA = azathioprine * BOS--bronchiolitis obliterans syndrome stage (ranges from 0 to 3) ** daily dose of Prednisone is indicated in brackets Table 4. Intramuscular Fat Infiltration Transplant COPD Interquartile Range Rectus Femoris 54.8 [+ or -] 10.1 54.7 [+ or -] 9.8 Vasti 56.1 [+ or -] 11.4 64.8 [+ or -] 19.9 Semitendinosis 65.7 [+ or -] 12.3 87.6 [+ or -] 30.1 Biceps Femoris (long head) 68.6 [+ or -] 18.7 83.6 [+ or -] 30.3 Coefficient of Skewness Rectus Femoris 1.65 [+ or -] 0.60 2.05 [+ or -] 0.67 Vasti 1.71 [+ or -] 0.60 2.05 [+ or -] 0.67 Semitendinosis 2.09 [+ or -] 0.39 1.91 [+ or -] 0.59 Biceps Femoris (long head) 1.74 [+ or -] 0.89 1.41 [+ or -] 0.28 Mean Difference (95% CI) Interquartile Range Rectus Femoris 0.04 (-12.8 to 12.8) Vasti -8.76 (-28.9 to 11.4) Semitendinosis -21.9 (-50.4 to 6.57) Biceps Femoris (long head) -15.0 (-46.1 to 16.0) Coefficient of Skewness Rectus Femoris -0.40 (-1.29 to 0.50) Vasti -0.33 (-1.39 to 0.72) Semitendinosis -0.19 (-0.80 to 1.17) Biceps Femoris (long head) 0.34 (-0.48 to 1.16) Mean and 95% confidence interval (95% CI) for differences intramuscular fat infiltration in transplant recipients and people with COPD. Intramuscular fat infiltration was described using interquartile range and skewness of the frequency distributions of signal intensity.
|Printer friendly Cite/link Email Feedback|
|Author:||Mathur, Sunita; Levy, Robert D.; Reid, W. Darlene|
|Publication:||Cardiopulmonary Physical Therapy Journal|
|Article Type:||Clinical report|
|Date:||Sep 1, 2008|
|Previous Article:||The evidence regarding exercise training in the management of cystic fibrosis: a systematic review.|
|Next Article:||Outcomes in cardiopulmonary physical therapy: acute care index of function.|